Navigation Links
CryoLife 2012 Annual Revenues Grew to a Record $131.7 Million
Date:2/14/2013

160;This includes expectations for BioGlue and BioFoam revenues to increase in the mid-single digits on a percentage basis in 2013 compared to 2012, and PerClot revenues to be between $3.5 million and $4.0 million, which represents growth of 13 percent to 29 percent compared to 2012.  The Company expects revenues from the HeRO Graft to increase to between $6.0 and $7.0 million, which represents growth of 20 percent to 40 percent compared to the annualized fourth quarter 2012 run rate.  The Company expects revenues from revascularization technologies to be between $8.5 million and $9.0 million in 2013, which represents growth of 5 percent to 11 percent. 

Research and development expenses are expected to be between $11.0 million and $12.0 million in 2013, a 52 percent to 65 percent increase, primarily as a result of the Company's investments in its U.S. clinical trials for PerClot. 

The Company expects earnings per share of between $0.25 and $0.28 in 2013, which includes the increased research and development expenses described above and the anticipated impact of the U.S. medical device excise tax implemented in 2013 as part of the Affordable Care Act.  The Company's earnings per share guidance excludes expenses related to business development and potential share repurchases, which cannot currently be estimated. 

The Company expects the effective income tax rate for 2013 to be in the mid thirty percent range. 

The Company's financial guidance for the full year of fiscal 2013 is subject to the risks described below in the last paragraph of this press release, prior to the financial tables.

Webcast and Conference Call InformationThe Company will hold a teleconference call and live webcast today at 10:00 a.m. Eastern Time to discuss the results followed by a question and answer session hosted by Mr. Anderson.

To listen to the live teleconference, please dial 201-689-8261 a few minutes prior
'/>"/>

SOURCE CryoLife, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

Related medicine technology :

1. CryoLife Reports Record Quarterly Revenues in First Quarter of 2012
2. CryoLife Completes Acquisition of Hemosphere
3. CryoLife to Participate in 3rd Annual Benchmark Company, LLC One-on-One Investor Conference
4. CryoLife Announces Release Date and Teleconference Call Details for 2012 Second Quarter Financial Results
5. CryoLife Reports 13% Revenue Growth for Second Quarter 2012
6. CryoLife Announces Initiation of Quarterly Cash Dividend
7. CryoLife Reports 13% Revenue Growth for Third Quarter 2012
8. CryoLife to Participate in Lazard Capital Markets 9th Annual Healthcare Conference
9. CryoLife Receives Expanded Indication for BioFoam in Europe
10. CryoLife Announces Release Date and Teleconference Call Details for 2012 Fourth Quarter and Year End Financial Results
11. CryoLife Announces Quarterly Cash Dividend for the First Quarter 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... Feb. 27, 2015 An aggressive campaign to ... the rate of infection with a dangerous drug-resistant bacteria ... Clostridium difficile, or C.diff, is a bacterium that ... of the colon. A recent article in the New ... Infection in the United States " ...
(Date:2/27/2015)... --  Synageva BioPharma Corp. (Synageva) (NASDAQ: ... products for rare diseases, joins the National Organization ... Rare Diseases™ (EURORDIS™), The Global Genes Project™, and ... Day. On the last day of ... participants conduct special events to raise awareness and ...
(Date:2/27/2015)... 27, 2015  PTC Therapeutics, Inc. (NASDAQ: ... financial results for the fourth quarter and full year ... a transformative year for PTC. We are now a ... RNA-targeted therapies in the rare disease space," stated Stuart ... "We are proud to bring the first treatment for ...
Breaking Medicine Technology:Curb Overuse Of Antibiotics To Reduce Drug-Resistant Superbug 2Curb Overuse Of Antibiotics To Reduce Drug-Resistant Superbug 3Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 2Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 3Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 4Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 5Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 6PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 2PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 3PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 4PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 5PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 6PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 7PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 8PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 9PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 10PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 11
... Biotech, Inc. is pleased to,announce that it ... (PCT) patent from Australia, China and India. ... their Method of use for Gut-based,Therapy," protects ... oral,probiotic product formulation (Kibow Biotics(R)) which may ...
... Therapies Shows Similar, Sustained Response Rates; Fewer Patients ... ... KENILWORTH, N.J., Jan. 14 Schering-Plough,Corporation (NYSE: SGP ... of the IDEAL study, the first large, randomized, clinical,study comparing ...
Cached Medicine Technology:Kibow Biotech Obtains Australian, Chinese and Indian Patents Protecting the Composition and Basic Technology Behind Its Oral Probiotic Formulation for Chronic Kidney Failure 2Kibow Biotech Obtains Australian, Chinese and Indian Patents Protecting the Composition and Basic Technology Behind Its Oral Probiotic Formulation for Chronic Kidney Failure 3Schering-Plough Reports Top-Line Results of the IDEAL Study 2Schering-Plough Reports Top-Line Results of the IDEAL Study 3Schering-Plough Reports Top-Line Results of the IDEAL Study 4Schering-Plough Reports Top-Line Results of the IDEAL Study 5Schering-Plough Reports Top-Line Results of the IDEAL Study 6Schering-Plough Reports Top-Line Results of the IDEAL Study 7Schering-Plough Reports Top-Line Results of the IDEAL Study 8Schering-Plough Reports Top-Line Results of the IDEAL Study 9
(Date:2/28/2015)... TN: MedixSafe has retracted a previous announcement from ... named Guardian 2. The correct product name is ... that significantly increases the complexity of security credentials. ... provides fast and easy access for both the ... with Vanguard technology tracks inventory by time, ...
(Date:2/28/2015)... 28, 2015 My Shiney Hiney® LLC., the ... team to Las Vegas, Nevada for the annual ASD Market ... of the leading consumer-goods tradeshows and My Shiney Hiney will ... event. My Shiney Hiney can be found at booth number ... for the at-home personal hygiene brush and cleansing system exclusively ...
(Date:2/27/2015)... Sacramento, Calif. (PRWEB) February 27, 2015 ... of liver-disease death, between four and 12 years earlier ... study from UC Davis Health System. , While previous ... ALD than other populations, the new study -- published ... -- is believed to be the first to pinpoint ...
(Date:2/27/2015)... Clara, CA (PRWEB) February 27, 2015 ... Passive Devices (IPD), has introduced miniature, wire bondable, silicon ... and Power LED markets. The ESD88NP ... transient currents away from sensitive LED and IC products. ... to Multilayer Varistors (MLV). All devices meet the ...
(Date:2/27/2015)... 2015 Just a little over two ... suffering from Sjögren’s Syndrome after a new autoantibody associated ... the University of Buffalo and Immco Diagnostics, Inc. After ... to develop a new diagnostic test that ... new autoantibodies. Researchers aimed to develop a test that ...
Breaking Medicine News(10 mins):Health News:New Name Announced For Newest MedixSafe Readers – MedixSafe Vanguard 2Health News:My Shiney Hiney® to Participate in ASD Market Week 2015 2Health News:UC Davis Study Finds Hispanics Develop Alcoholic Liver Disease at Younger Ages than Caucasians or African Americans 2Health News:OnChip Introduces New Series of Space Saving Bare-die Zener Diodes for Transient Voltage Suppression 2Health News:OnChip Introduces New Series of Space Saving Bare-die Zener Diodes for Transient Voltage Suppression 3Health News:Breakthrough Blood Test for Early Detection of Sjögren’s Syndrome Now Available 2
... , , Recognize Excellence in Reporting, Portrayals ... 31 , ALEXANDRIA, Va. , Feb. ... professionals to submit national, state, local and student news and ... the 2010 Media Awards. , Details, including categories and a ...
... , , TUCSON, Ariz. , Feb. 9 ... largest companies with over 11,000 employees nationwide, today announced that it ... , Providence , working with Peach Properties, will take over ... to the new site of Tucson Electric Power,s new headquarters. , ...
... ... extensive smile gallery and other resources and tools for patients , ... New York, NY (PRWEB) February 9, 2010 -- Leading ... the launch of its new Web site, www.SmileInTheCity.com . The site boasts simple navigation, ...
... biopsies done in doctor,s office boosted overall spending, study ... Medicare sweetened payments for simple office-based endoscopic procedures, doctors ... in-office bladder biopsies, but the volume of hospital procedures ... So, instead of saving money, Medicare expenditures rose 50 ...
... Feb. 9 Quantum Health, the Columbus, ... appointed Jim Stark to be Executive Vice President ... Director for Aon Consulting, will oversee Quantum Health,s national sales ... various Blue Cross/Blue Shield plans, national insurance carriers and third ...
... ... their teens a gift of knowledge and empowerment, because when romance heats up, teens often ... ... having ,The Talk, is probably one of the most difficult and challenging moments of parenthood. ...
Cached Medicine News:Health News:Mental Health America Encourages Journalists, Media Professionals to Submit Entries for 2010 Media Awards 2Health News:Mental Health America Encourages Journalists, Media Professionals to Submit Entries for 2010 Media Awards 3Health News:Providence Service Corporation Relocates Corporate Headquarters to Downtown Tucson 2Health News:Providence Service Corporation Relocates Corporate Headquarters to Downtown Tucson 3Health News:Top New York Dentists at Smile in the City Launch New Web Site 2Health News:Medicare Cost-Saving Moves Can Backfire 2Health News:Medicare Cost-Saving Moves Can Backfire 3Health News:Quantum Health Appoints Stark as Executive Vice President of Sales 2Health News:Don't Be a Sex Ed Horror Story — Keep the VD Out of Valentine's Day 2Health News:Don't Be a Sex Ed Horror Story — Keep the VD Out of Valentine's Day 3
Thermal Seal, Clear, Bulk...
Mylar Plate Sealers 100/Box...
OptiTape - Optically Clear sealing tape for OmniUltra PCR plates plus universal dispenser. 250 sheets....
The Heat Sealing Foil and Heat...
Medicine Products: